

=> d ibib ab 1-9

L3 ANSWER 1 OF 9 USPATFULL
 ACCESSION NUMBER: 1999:24300 USPATFULL
 TITLE: Occlusive/semi-occlusive lotion for treatment of a skin disease or disorder
 INVENTOR(S): Smith, James A., Chatham, MA, United States
 PATENT ASSIGNEE(S): Creative Products Resource Associates Inc., North Caldwell, NJ, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5874074	19990223
APPLICATION INFO.:	US 1997-804084	19970221 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1995-480534, filed on 7 Jun 1995, now patented, Pat. No. US 5658559 which is a continuation of Ser. No. US 1994-220394, filed on 30 Mar 1994, now abandoned which is a continuation of Ser. No. US 1992-992887, filed on 16 Dec 1992, now abandoned	
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Harrison, Robert H.	
LEGAL REPRESENTATIVE:	Pillsbury Madison & Sutro Intellectual Property Group	
NUMBER OF CLAIMS:	17	
EXEMPLARY CLAIM:	1	
LINE COUNT:	711	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB The present invention is an occlusive or semi-occlusive barrier moisturizing lotion useful for treating pathologies of the skin. The lotion is composed of an oil-in-water emulsion that includes water, one or more emollients, at least one polyhydric alcohol, a barrier polymer, and a therapeutic agent, preferably a dermatological agent such as a steroid. When the lotion is applied to the skin and dries, a polymeric film forms on the surface of the lotion to retain the therapeutic agent in contact with the surface of the skin. The emollient system of the lotion provides a moisturizing and soothing effect on the skin, and the occlusive/semi-occlusive nature of the lotion causes hydration of the skin to facilitate and enhance penetration of the drug into the skin.

L3 ANSWER 3 OF 9 USPATFULL
 ACCESSION NUMBER: 95:50185 USPATFULL
 TITLE: Stable cream and lotion bases for lipophilic drug compositions
 INVENTOR(S): Munayyer, Farah J., West Caldwell, NJ, United States
 PATENT ASSIGNEE(S): Sequeira, Joel A., New York, NY, United States
 Schering Corporation, Kenilworth, NJ, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5422361	19950606
APPLICATION INFO.:	WO 9108733	19910627
RELATED APPLN. INFO.:	US 1992-859494 19920612 (7) WO 1990-US7228 19901214 19920612 PCT 371 date 19920612 PCT 102(e) date	
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Cintins, Marianne M.	
ASSISTANT EXAMINER:	Criares, T. J.	
LEGAL REPRESENTATIVE:	Hoffman, Thomas D.	
NUMBER OF CLAIMS:	10	
EXEMPLARY CLAIM:	1	
LINE COUNT:	913	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB A cosmetically elegant, physically and chemically stable base in the form of an oil-in-water emulsion for use in cream and lotion lipophilic drug containing- pharmaceutical compositions containing at least one lipophilic drug and an effective amount of N-methyl-2-pyrrolidone is disclosed.

L3 ANSWER 2 OF 9 USPATFULL
 ACCESSION NUMBER: 97:73278 USPATFULL
 TITLE: Occlusive/semi-occlusive lotion for treatment of a skin disease or disorder
 INVENTOR(S): Smith, James A., Chatham, MA, United States
 PATENT ASSIGNEE(S): Creative Products Resource Associates, Ltd., North Caldwell, NJ, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5658559	19970819
APPLICATION INFO.:	US 1995-480534	19950607 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1994-220394, filed on 30 Mar 1994, now abandoned which is a continuation of Ser. No. US 1992-992887, filed on 16 Dec 1992, now abandoned	
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Hulina, Amy	
LEGAL REPRESENTATIVE:	Cushman Darby & Cushman IP Group of Pillsbury Madison & Sutro, LLP	
NUMBER OF CLAIMS:	2	
EXEMPLARY CLAIM:	1	
LINE COUNT:	638	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB The present invention is an occlusive or semi-occlusive barrier moisturizing lotion useful for treating pathologies of the skin. The lotion is composed of an oil-in-water emulsion that includes water, one or more emollients, at least one polyhydric alcohol, a barrier polymer, and a therapeutic agent, preferably a dermatological agent such as a steroid. When the lotion is applied to the skin and dries, a polymeric film forms on the surface of the lotion to retain the therapeutic agent in contact with the surface of the skin. The emollient system of the lotion provides a moisturizing and soothing effect on the skin, and the occlusive/semi-occlusive nature of the lotion causes hydration of the skin to facilitate and enhance penetration of the drug into the skin.

L3 ANSWER 4 OF 9 USPATFULL
 ACCESSION NUMBER: 95:33913 USPATFULL
 TITLE: Method of treating inflammatory conditions of the mouth using steroid containing mouthwash which may contain antifungal agents
 INVENTOR(S): Eisen, Dror, 6720 Beechlands Dr., Cincinnati, OH, United States 45237

	NUMBER	DATE
PATENT INFORMATION:	US 5407663	19950418
APPLICATION INFO.:	US 1994-222277	19940404 (8)
RELATED APPLN. INFO.:	20110510 Continuation-in-part of Ser. No. US 1993-6287, filed on 15 Jan 1993, now patented, Pat. No. US 5310545	
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Mars, Howard T.	
ASSISTANT EXAMINER:	Cook, Rebecca	
LEGAL REPRESENTATIVE:	Hendricks, Glenn; Gates, Stephen	
NUMBER OF CLAIMS:	12	
EXEMPLARY CLAIM:	1	
LINE COUNT:	422	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB Patients may effectively be treated for inflammatory conditions of the mouth using aqueous anti-inflammatory steroids in solutions that can be swished and expectorated as a mouthwash. Such therapy would allow direct contact of the medication with the diseased mucous membranes and would contact areas of the oral cavity that would not usually be reached with application of creams, gels, or ointments. Compositions containing antifungal agents in addition to steroids are particularly useful. Swishing for three to five minutes, then expectorating the aqueous anti-inflammatory-containing, results in maintenance of contact of the active agents with the oral cavity surfaces for a longer time than would application of gels containing those agents. The mode of application is simple and is not repugnant to the patient as is the application of creams, gels, or ointments.

L3 ANSWER 4 OF 9 USPATFULL (Continued)

L3 ANSWER 5 OF 9 USPATFULL
ACCESSION NUMBER: 94:39864 USPATFULL
TITLE: Method of treatment using mouthwashes containing steroids and antifungal agents and compositions of matter
INVENTOR(S): Eisen, Drore, 6720 E. Beechlands Dr., Cincinnati, OH,
United States 65237

	NUMBER	DATE
PATENT INFORMATION:	US 5310545	19940510
APPLICATION INFO.:	US 1993-6287	19930115 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1992-963485, filed on 21 Oct 1992 And a continuation-in-part of Ser. No. US 1991-802646, filed on 9 Dec 1991, now abandoned which is a continuation-in-part of Ser. No. US 1991-683380, filed on 11 Apr 1991, now abandoned	
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Cintins, Marianne M.	
ASSISTANT EXAMINER:	Cook, Rebecca	
LEGAL REPRESENTATIVE:	Hendericks, Glenna; Gates, Stephen	
NUMBER OF CLAIMS:	20	
EXEMPLARY CLAIM:	1	
LINE COUNT:	408	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions used to treat inflammatory diseases of the mouth contain anti-inflammatory steroids in combination with antifungal drugs in an aqueous medium as a mouthwash. Swishing for three to five minutes, then expectorating the mouthwashes results in maintenance of contact of the active agents with the oral cavity surfaces for a longer time than would application of gels containing those agents. The mode of application is simple and is not repugnant to the patient as is the application of creams, gels, or ointments.

L3 ANSWER 6 OF 9 USPATFULL
ACCESSION NUMBER: 91:89045 USPATFULL
TITLE: Glyceryl acetate ointment vehicles
INVENTOR(S): Dow, Gordon J., 506 Sequoia Ave., San Anselmo, CA, United States 94960
Dow, Debra A., San Rafael, CA, United States
Dow, Gordon Jay, Mill Valley, CA, United States
PATENT ASSIGNEE(S):
(U.S. individual)

	NUMBER	DATE
PATENT INFORMATION:	US 5061700	19911029
APPLICATION INFO.:	US 1989-438372	19891116 (7)
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Rose, Shep K.	
LEGAL REPRESENTATIVE:	Townsend and Townsend	
NUMBER OF CLAIMS:	17	
EXEMPLARY CLAIM:	1	
LINE COUNT:	642	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions of matter serving as topical ointment vehicles and comprising a glyceryl acetate, preferably triacetin, and an oleaginous material that can be combined with a medicament, preferably a corticosteroid, are described. The glyceryl acetate component functions as a solvent for the medicament. Additionally, methods of use for treating skin disorders comprising the topical application of a therapeutically effective amount of a medicament in a composition of the invention are detailed.

L3 ANSWER 7 OF 9 USPATFULL
ACCESSION NUMBER: 88:63905 USPATFULL
TITLE: Steroid lotion
INVENTOR(S): Sequeira, Joel A., New York, NY, United States
Munayyer, Farah J., West Caldwell, NJ, United States
States
Galeos, Rebecca, Bloomfield, NJ, United States
Schering Corporation, Kenilworth, NJ, United States (U.S. corporation)
PATENT ASSIGNEE(S):

	NUMBER	DATE
PATENT INFORMATION:	US 4775529	19881004
APPLICATION INFO.:	US 1987-53172	19870521 (7)
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Rose, Shep K.	
LEGAL REPRESENTATIVE:	Maltner, John J.; Miller, Stephen I.; Nelson, James R.	
NUMBER OF CLAIMS:	18	
EXEMPLARY CLAIM:	1	
LINE COUNT:	291	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB An improved lotion formulation for the topical administration of corticosteroids in a hydro-alcoholic base containing propylene glycol.

L3 ANSWER 8 OF 9 USPATFULL
 ACCESSION NUMBER: 78:62796 USPATFULL
 TITLE: 7.alpha.-Halogeno-3,20-dioxo-1,4-pregnadienes,
 methods for their manufacture, their use as
 anti-inflammatory agents, and pharmaceutical formulations useful
 therefor
 INVENTOR(S): Green, Michael J., Kendall Park, NJ, United States
 Shue, Ho-Jane, Belleville, NJ, United States
 PATENT ASSIGNEE(S): Schering Corporation, Kenilworth, NJ, United States
 (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 4124707	19781107
APPLICATION INFO.:	US 1977-849856	19771107 (5)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1976-753256, filed on 12 Dec 1976, now abandoned	
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Roberts, Elbert L.	
LEGAL REPRESENTATIVE:	King, Mary S.	
NUMBER OF CLAIMS:	29	
EXEMPLARY CLAIM:	1,23	
LINE COUNT:	3271	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB Novel 3,20-dioxo-7.alpha.-halogeno-1,4-pregnadienes are described
 and their use as anti-inflammatory agents. Preferred are
 7.alpha.-bromo- and 7.alpha.-chloro- derivatives, particularly 7.alpha.-bromo- and
 7.alpha.-chloro-1,4-pregnadienes-11.beta.,17.alpha.,21-triol-3,20-dione
 17,21-dihydrocarboncarboxylates, the 16-methyl and 16-methylene
 derivatives thereof being particularly valuable as topical
 anti-inflammatory agents.

L3 ANSWER 9 OF 9 USPATFULL (Continued)

L3 ANSWER 9 OF 9 USPATFULL
 ACCESSION NUMBER: 78:11581 USPATFULL
 TITLE: Process for the preparation of
 7.alpha.-halogeno-3-oxo-4-dehydro steroids and novel 7.alpha.-halogeno
 derivatives produced thereby
 INVENTOR(S): Green, Michael J., Kendall Park, NJ, United States
 Shue, Ho-Jane, Belleville, NJ, United States
 Shapiro, Elliot L., Cedar Grove, NJ, United States
 Gentles, Margaret A., Bloomfield, NJ, United States
 PATENT ASSIGNEE(S): Schering Corporation, Kenilworth, NJ, United States
 (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 4076708	19780228
APPLICATION INFO.:	US 1976-753257	19761222 (5)
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Roberts, Elbert L.	
LEGAL REPRESENTATIVE:	King, Mary S.; Coan, Stephen B.	
NUMBER OF CLAIMS:	18	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1422	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB 3-Oxo-6-unsubstituted-7.alpha.-halogeno-4-dehydro steroids, wherein
 said halogen is chlorine, bromine or iodine, are prepared by reaction of
 a 3-oxo-6,7-di-unsubstituted-4,6-bis-dehydro steroid with at least an
 equimolar quantity of the corresponding hydrogen halide in a
 non-reactive organic solvent at temperatures no higher than about
 30.degree. C, and then are isolated by removal of said solvent and
 any excess acid at temperatures no higher than about 25.degree. C
 without subjecting said 3-oxo-6-unsubstituted-7.alpha.-halogeno-4-dehydro
 steroid to a basic medium.
 A preferred species of this process is that wherein the starting
 steroid is a 3,20-dioxo-9-unsubstituted-11-oxygenated-1,4,6-pregnatriene-17,21-
 diol or ester thereof, preferably a 17,21-di-lower alkanate or a
 17-benzoate 21-lower alkanate ester thereof, whereby is prepared in
 good yields a 3,20-dioxo-7.alpha.-halogeno-1,4-pregnadiene-17.alpha.,21-
 diol or ester thereof, useful as topical anti-inflammatory agents.
 Also described are novel 3,20-dioxo-7.alpha.-halogeno-4-pregnene-
 17.alpha.,21-diols and esters thereof having anti-inflammatory
 activity as well as 3-oxo-7.alpha.-halogeno-17.alpha.-4-pregnene-21,17.beta.-
 carbolactone aldosterone antagonists.

=> d ibib ab hit 1-7

L5 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2000 ACS
 ACCESSION NUMBER: 1999:522135 CAPLUS
 DOCUMENT NUMBER: 131:134676
 TITLE: Antipsoriatic nail polishes containing glucocorticoids
 INVENTOR(S): Bohn, Manfred; Kraemer, Karl Theodor
 PATENT ASSIGNEE(S): Hoechst Marion Roussel Deutschland GmbH, Germany
 SOURCE: Can. Pat. Appl., 13 pp.
 CODEN: CPXKEE
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CA 2245637	AA	19990221	CA 1998-2245637	19980820
EP 913154	A1	19990506	EP 1998-115049	19980811

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC,
 PT, IE, SI, LT, LV, FI, RO
 NO 9803818 A 19990222 NO 1998-3818 19980820
 ZA 9807531 A 19990222 ZA 1998-7531 19980820
 CN 1209318 A 19990303 CN 1998-118470 19980820
 AU 9880856 A1 19990304 AU 1998-80856 19980820
 JP 11130679 A2 19990518 JP 1998-233671 19980820
 DE 1997-19736112 19970821

PRIORITY APPLN. INFO.:
 AB A nail polish comprises at least one glucocorticoid, at least one physiol. acceptable solvent and at least one water-insol. film-forming agent.
 The nail polish is suitable for the treatment of nail psoriasis. A nail polish contained clobetasol-17-propionate 8, Me vinyl ether-monoethyl maleate copolymer (in isopropanol) 30, isopropanol 31, and EtOAc 31 %.
 AB A nail polish comprises at least one glucocorticoid, at least one physiol. acceptable solvent and at least one water-insol. film-forming agent.
 The nail polish is suitable for the treatment of nail psoriasis. A nail polish contained clobetasol-17-propionate 8, Me vinyl ether-monoethyl maleate copolymer (in isopropanol) 30, isopropanol 31, and EtOAc 31 %.
 ST nail polish glucocorticoid polymer film psoriasis; clobetasol polyvinyl nail polish psoriasis
 IT Nail (anatomical) (disease, psoriasis; antipsoriatic nail polishes contg. glucocorticoids and film-forming polymers)
 IT Psoriasis (in nail; antipsoriatic nail polishes contg. glucocorticoids and film-forming polymers)
 IT 50-02-2, Dexamethasone 50-24-8, Prednisolone 53-03-2, Prednisone 67-73-2 72-80-0, Chlorquinaldol 76-25-5, Triamcinolone acetonide

L5 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2000 ACS
 ACCESSION NUMBER: 1998:603197 CAPLUS
 DOCUMENT NUMBER: 129:184277
 TITLE: Tazarotene and corticosteroid treatment for skin proliferation disorders, including psoriasis
 INVENTOR(S): Sefton, John
 PATENT ASSIGNEE(S): Vision Pharmaceuticals L.P., USA
 SOURCE: PT Int. Appl., 22 pp.
 CODEN: PIXK02
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9836753	A1	19980827	WO 1998-US3355	19980220

W: AU, CA, JP, US
 RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
 PT, SE
 AU 9866618 A1 19980909 AU 1998-66618 19980220
 EP 969847 A1 20000112 EP 1998-908631 19980220
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC,
 PT, IE, FI
 PRIORITY APPLN. INFO.:
 US 1997-39151 19970220
 WO 1998-US3355 19980220
 AB A method for treating proliferative skin diseases comprises the administration of an effective amt. of tazarotene and an effective amt. of a corticosteroid. This invention is esp. useful for treating psoriasis.
 TI Tazarotene and corticosteroid treatment for skin proliferation disorders, including psoriasis
 AB A method for treating proliferative skin diseases comprises the administration of an effective amt. of tazarotene and an effective amt. of a corticosteroid. This invention is esp. useful for treating psoriasis.
 ST skin proliferative disorder tazarotene corticosteroid; psoriasis tazarotene corticosteroid
 IT Skin tumors (inhibitors; tazarotene and corticosteroid treatment for skin proliferation disorders, including psoriasis)
 IT Skin diseases (proliferative; tazarotene and corticosteroid treatment for skin proliferation disorders, including psoriasis)
 IT Antitumor agents (skin; tazarotene and corticosteroid treatment for skin proliferation disorders, including psoriasis)
 IT Antiproliferative agents
 Creams (drug delivery systems)
 Drug interactions
 Gels (drug delivery systems)
 Psoriasis
 Topical drug delivery systems

L5 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2000 ACS (Continued)
 76-47-1, Hydrocortamate 130-26-7, Clotrimazole 152-97-6,
 Fluocortolone 382-67-2, Desoximetasone 426-13-1,
 Fluorometholone 638-94-8, Desonide 1255-35-2, Fluprednidene acetate 1524-88-5, Fludroxycortide 2002-29-1, Flumethasone pivalate 2152-44-5,
 Betamethasone valerate 2193-87-5, Fluprednidene 3093-35-4, Halcinonide 3693-39-8, Fluclorolone acetonide 5534-09-8, Beclomethasone dipropionate 5593-20-4, Betamethasone dipropionate 7008-26-6, Dichlorisone 9004-57-3, Ethyl cellulose 9004-70-0, Cellulose nitrate 13609-67-1,
 Hydrocortisone butyrate 19888-56-3, Fluazacort 22298-29-9, Betamethasone benzoate 23674-86-4, Difluprednate 25119-68-0,
 Methyl vinyl ether-monoethyl maleate copolymer 25122-46-7, Clobetasol propionate 25122-57-0, Clobetasone butyrate 25122-88-8,
 Methacrylic acid-ethyl acrylate copolymer 33564-31-7, Diflorasone diacetate 50629-82-8, Halometasone 51022-69-6, Amcinonide 51333-22-3,
 Budesonide 53716-43-1, Bendacort 55461-42-2, Flupamesone 59198-70-8, Diflucortolone valerate 61951-99-3, Triamcinolone 66734-13-2, Alclometasone dipropionate 67907-01-1 73771-04-7, Prednicarbate 83919-23-7, Mometasone furoate 86401-95-8, Methylprednisolone aceponate
 RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (antipsoriatic nail polishes contg. glucocorticoids and film-forming polymers)

L5 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2000 ACS (Continued)
 (tazarotene and corticosteroid treatment for skin proliferation disorders, including psoriasis)
 IT Corticosteroids, biological studies
 RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (tazarotene and corticosteroid treatment for skin proliferation disorders, including psoriasis)
 IT 50-03-3, Hydrocortisone acetate 67-73-2, Fluocinolone acetonide 356-12-7, Fluocinonide 807-38-5, Fluocinolone 2152-44-5,
 Betamethasone valerate 5593-20-4, Betamethasone dipropionate 25122-46-7,
 Clobetasol propionate 33564-31-7, Diflorasone diacetate 66734-13-2, Alclometasone dipropionate 80474-14-2, Fluticasone propionate 83919-23-7, Mometasone furoate 118292-40-3, Tazarotene
 RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (tazarotene and corticosteroid treatment for skin proliferation disorders, including psoriasis)

AB	A method for the treatment of skin disorders comprises the application of a formulation consisting of a glucocorticosteroid and a pharmaceutically acceptable zinc compd. The zinc compd. may be zinc monoglycerolate. The efficacy of topical zinc monoglycerolate was
equiv.	to that of 1% hydrocortisone ointment in the treatment of atopic dermatitis.
TI	Glucocorticoids and zinc compound for the treatment of skin disorders.
AB	A method for the treatment of skin disorders comprises the application of a formulation consisting of a glucocorticosteroid and a pharmaceutically acceptable zinc compd. The zinc compd. may be zinc monoglycerolate. The efficacy of topical zinc monoglycerolate was
equiv.	to that of 1% hydrocortisone ointment in the treatment of atopic dermatitis.
ST	skin disorder glucocorticoid zinc compd; topical glucocorticoid zinc compd skin disorder
IT	Atopic dermatitis Creams (drug delivery systems) Gels (drug delivery systems)

L5 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2000 ACS (Continued)

Lozems (drug delivery systems)

Ointments (drug delivery systems)

Skin diseases

Topical drug delivery systems

(glucocorticoids and zinc compd. for treatment of skin disorders)

IT Glucocorticoids

RI: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(glucocorticoids and zinc compd. for treatment of skin disorders)

IT 50-02-2, Dexamethasone 50-23-7, Hydrocortisone 53-36-1, Methylprednisolone acetate 67-73-2, Flucinolone acetonide

76-25-5, Triamcinolone acetonide 303-40-2, Flucortolone hexanoate

356-12-7, Flucinolone 382-67-2, Desoximethasone 638-94-8, Desonide

1177-87-3,

Dexamethasone acetate 1255-35-2, Fluprednidene acetate 1524-88-5, Fludrocortiside 2002-29-1, Flumethasone pivalate 2152-44-5, Betamethasone valerate 3093-35-4, Halcinonide 3693-39-8,

Fluoclorolone

acetonide 5534-09-8, Beclomethasone dipropionate 5593-20-4, Dexamethasone dipropionate 13609-67-1, Hydrocortisone butyrate 16754-68-0, Zinc monoglycerolate 22298-29-9, Clobetasol benzoate 23674-86-4, Difluprednate 25122-46-7, Clobetasol propionate 25122-57-0, Clobetasone butyrate 29205-06-9, Flucortolone pivalate 33564-31-7, Diflorasone diacetate 33755-46-3, Dexamethasone valerate 41767-29-7, Flucortin butyl ester 51022-69-6, Amcinonide

55541-30-5,

Dexamethasone dipropionate 59198-70-8, Difluocortolone valerate 66734-13-2, Alclometasone dipropionate 72604-79-0 72590-77-3 73771-04-7, Prednicarbate 83919-23-7, Mometasone furoate

98651-66-2,

Halobetasol

RI: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(glucocorticoids and zinc compd. for treatment of skin disorders)

L5 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2000 ACS
 ACCESSION NUMBER: 1996:656487 CAPLUS
 DOCUMENT NUMBER: 125:284968
 TITLE: Corticosteroid-containing pharmaceutical
 composition
 INVENTOR(S): Jones, Julie Irene; Baker, Anthony Richard; Halls, Neil Graham; Watmough, Peter; Marriott, Peter
 PATENT ASSIGNEE(S): Medeva Plc, UK
 SOURCE: PCT Int. Appl., 20 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9627376	A1	19960912	WO 1996-GB490	19960301
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, RW, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, CA 2214436 AA 19960912 CA 1996-2214436 19960301				
AU 9648851	A1	19960923	AU 1996-48851	19960301
AU 709320	B2	19990826		
EP 813413	A1	19971229	EP 1996-904935	19960301
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
CN 1179720	A	19980422	CN 1996-192817	19960301
JP 11501045	T2	19990126	JP 1996-526697	19960301
CZ 285913	B6	19991117	CZ 1997-2758	19960301
BR 9607687	A	19991130	BR 1996-7687	19960301
GB 1995-4265 19950303				
WO 1996-GB490 19960301				

PRIORITY APPL. INFO.:
 AB The present invention provides a foamable pharmaceutical compn. comprising a corticosteroid active substance, a quick-break foaming agent, a propellant, and a buffering agent. The quick-break foaming agent typically comprises an aliph. alc., water, a fatty alc. and surface active agent. The compns. of the invention can be used to treat various skin disease, and in particular scalp psoriasis. A claimed compn. contains betamethasone valerate 0.12, cetyl alc. 1.1, octadecan-1-ol 0.5, Polysorbate-60 0.4, ethanol 57.79, purified water 33.69, propylene glycol 2, anhyd. citric acid 0.073, K citrate 0.027, and

L5 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2000 ACS (Continued)
 butane/propane 4.3 %.
 AB The present invention provides a foamable pharmaceutical compn. comprising a corticosteroid active substance, a quick-break foaming agent, a propellant, and a buffering agent. The quick-break foaming agent typically comprises an aliph. alc., water, a fatty alc. and surface active agent. The compns. of the invention can be used to treat various skin disease, and in particular scalp psoriasis. A claimed compn. contains betamethasone valerate 0.12, cetyl alc. 1.1, octadecan-1-ol 0.5, Polysorbate-60 0.4, ethanol 57.79, purified water 33.69, propylene glycol 2, anhyd. citric acid 0.073, K citrate 0.027, and butane/propane 4.3 %.
 ST foam corticosteroid skin disease
 IT Eczema
 Psoriasis
 (treatment of; corticosteroid-contg. pharmaceutical foamable compn.)
 IT Scalp (disease, psoriasis, treatment of; corticosteroid-contg. pharmaceutical foamable compn.)
 IT Skin, disease (intertrigo, treatment of; corticosteroid-contg. pharmaceutical foamable compn.)
 IT 50-03-3, Hydrocortisone acetate 50-23-7, Hydrocortisone 53-36-1, Methylprednisolone acetate 67-73-2, Fluocinolone acetonide 76-25-5, Triamcinolone acetonide 152-97-6, Fluocortolone 356-12-7, Fluocinonide 382-67-2, Desoxymethasone 638-94-8, Desonide 1255-35-2, Fluprednidene acetate 1524-88-5, Flurandrenolone 2002-29-1, Flumethasone pivalate 2152-44-5, Betamethasone valerate 3093-35-4, Halcinonide 3693-39-8, Fluoclorolone acetonide 5534-09-8, Beclomethasone dipropionate 5593-20-4, Betamethasone dipropionate 13609-67-1, Hydrocortisone butyrate 22298-29-9, Betamethasone benzoate 25122-46-7, Clobetasol propionate 25122-57-0, Clobetasone butyrate 33564-31-7, Diflorasone disacetate 41767-29-7, Fluocortin butyl 51022-69-6, Amcinonide 51333-22-3, Budesonide 59198-70-8, Difluocortolone valerate 66734-13-2, Alclometasone dipropionate 83919-23-7, Mometasone furoate
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (corticosteroid-contg. pharmaceutical foamable compn.)

L5 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2000 ACS
 ACCESSION NUMBER: 1996:262517 CAPLUS
 DOCUMENT NUMBER: 124:298941
 TITLE: Water-base adhesive preparations of corticosteroids for skin diseases
 INVENTOR(S): Ikeura, Yasuhiro; Tsuru, Seichiro; Kubota, Jusuke
 PATENT ASSIGNEE(S): Hisanoteu Pharmaceutical Co, Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 6 pp.
 CODEN: JKOXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 08053354	A2	19960227	JP 1994-211951	19940811
AB The prepn. contain water-sol. polymers, moisturizers, H2O, dissolving agents and/or absorbefaciants, and corticosteroids selected from difluocortolone valerate, difluprednate, prednisolone valerate acetate, hydrocortisone butyrate propionate, diflorasone acetate, dexamethasone propionate, betamethasone dipropionate, amcinonide, dexamethasone valerate, halcinonide, budesonide, and alclometasone propionate. The prepn. show moisturizing effect and are mild to skin, and are useful for treatment of eczema, dermatitis, psoriasis, erythema, sting by insects, chronic discotic erythematous, lichen, atopic dermatitis, etc. A nonwoven fabric was coated with an adhesive compn. contg. H2O, gelatin, poly(vinyl alc.), kaolin, glycerin, poly(Na acrylate), methoxyethylene-maleic anhydride copolymer, difluocortolone valerate, and crotonit to give a adhesive prep. The prep. showed skin-paling action upon application to forearm of healthy male volunteers and had slight skin-irritating effect.				
TI Water-base adhesive preparations of corticosteroids for skin diseases				
AB The prepn. contain water-sol. polymers, moisturizers, H2O, dissolving agents and/or absorbefaciants, and corticosteroids selected from difluocortolone valerate, difluprednate, prednisolone valerate acetate, hydrocortisone butyrate propionate, diflorasone acetate, dexamethasone propionate, betamethasone dipropionate, amcinonide, dexamethasone valerate, halcinonide, budesonide, and alclometasone propionate. The prepn. show moisturizing effect and are mild to skin, and are useful for treatment of eczema, dermatitis, psoriasis, erythema, sting by insects, chronic discotic erythematous, lichen, atopic dermatitis, etc. A nonwoven fabric was coated with an adhesive compn. contg. H2O, gelatin, poly(vinyl alc.), kaolin, glycerin, poly(Na acrylate), methoxyethylene-maleic anhydride copolymer, difluocortolone valerate, and crotonit to give a adhesive prep. The prep. showed skin-paling action upon application to forearm of healthy male volunteers and had slight skin-irritating effect.				
IT Skin, disease (aq. corticosteroid adhesive prepn. contg. water-sol. polymers, moisturizers, and dissolving agents and/or absorbefaciants for skin diseases)				
IT Corticosteroids, biological studies Gelatins, biological studies RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)				

L5 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2000 ACS (Continued)
 (aq. corticosteroid adhesive prepn. contg. water-sol. polymers, moisturizers, and dissolving agents and/or absorbefaciants for skin diseases)
 IT Essential oils
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (peppermint, aq. corticosteroid adhesive prepn. contg. water-sol. polymers, moisturizers, and dissolving agents and/or absorbefaciants for skin diseases)
 IT Pharmaceutical dosage forms (topical, adhesives aq. corticosteroid adhesive prepn. contg. water-sol. polymers, moisturizers, and dissolving agents and/or absorbefaciants for skin diseases)
 IT 56-81-5, Glycerin, biological studies 57-55-6, Propylene glycol, biological studies 100-51-6, Benzyl alcohol, biological studies 110-27-0, Isopropyl myristate 483-63-6, Crotonit 3093-35-4, Halcinonide 5593-20-4, Betamethasone dipropionate 9002-89-5, Poly(vinyl alcohol) 9003-01-4, Poly(acrylic acid) 9003-04-7, Polyacrylic acid sodium salt 9003-39-8, Poly(vinylpyrrolidone) 9004-32-4, Carboxymethyl cellulose 9011-16-9, Methoxyethylene-maleic anhydride copolymer 23674-86-4, Difluprednate 25322-68-3, Polyethylene glycol 33564-31-7 33755-46-3, Dexamethasone valerate 51022-69-6, Amcinonide 51333-22-3, Budesonide 55541-30-5 59198-70-8, Difluocortolone valerate 66734-13-2 72064-79-0 72590-77-3
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (aq. corticosteroid adhesive prepn. contg. water-sol. polymers, moisturizers, and dissolving agents and/or absorbefaciants for skin diseases)

=> d his

(FILE 'HOME' ENTERED AT 14:01:33 ON 20 JUL 2000)

FILE 'REGISTRY' ENTERED AT 14:01:35 ON 20 JUL 2000
L1 1 S ALCLOMETASONE DIPROPIONATE/CN

FILE 'USPATFULL' ENTERED AT 14:02:03 ON 20 JUL 2000
L2 11 S L1
L3 9 S L2 AND (PSORIAS? OR SKIN)

FILE 'CAPLUS' ENTERED AT 14:04:48 ON 20 JUL 2000
L4 12 S L1/THU
L5 7 S L4 AND (PSORIAS? OR SKIN)



Creation date: 01-08-2004
Indexing Officer: NNGUYEN6 - NGUYEN NGUYEN
Team: OIPEBackFileIndexing
Dossier: 09367712

Legal Date: 07-21-2000

No.	Doccode	Number of pages
1	CTFR	7
2	892	1

Total number of pages: 8

Remarks:

Order of re-scan issued on